This trial is active, not recruiting.

Condition postpartum hemorrhage
Treatments tranexamic acid, placebo; normal saline
Phase phase 2
Sponsor Brigham and Women's Hospital
Start date July 2014
End date June 2017
Trial size 60 participants
Trial identifier NCT02026297, Tranexamic Acid TEG


The aim of this study is to characterize the coagulation changes, using thromboelastography (TEG), after prophylactic tranexamic administration during cesarean delivery. Specifically, TEG values will be compared in patients who receive prophylactic tranexamic acid or placebo before surgery, during elective cesarean delivery, and 2 hours postpartum.

Postpartum hemorrhage (PPH) is increasing in incidence in the United States, renewing interest in multimodal approaches to blood conservation during cesarean delivery. Pharmacologic therapy with the antifibrinolytic agent, tranexamic acid (TA), has been shown to reduce estimated blood loss (EBL) during cesarean delivery, but its effect on global coagulation as assessed by TEG, and how this correlates with lowering blood loss, has not been elucidated.

This study will be conducted as a randomized, double-blind, controlled trial with two study arms: control (60 patients); and treatment (60 patients).

Subjects will be pre-medicated with routine pre-cesarean delivery medications including oral sodium citrate 30 mL and intravenous (IV) metoclopramide 10 mg. A peripheral IV and noninvasive hemoglobin monitor will be placed, and baseline labs sent: type and screen, serum hemoglobin, platelet count, fibrinogen, activated partial thromboplastin time (aPTT), prothrombin time (PT), and baseline TEG values (r time, k time, alpha angle, and maximum amplitude). Patients will have blood pressure, heart rate, and pulse oximetry measured throughout surgery as per standard of care. Patients will all receive IV lactated Ringers' (LR) solution prior to surgery and throughout surgery, with volume recorded and a goal of less than 2 L unless more IV fluid is clinically indicated. All patients will have a spinal anesthetic as per standard of care, with hyperbaric bupivacaine 12 mg, fentanyl 10 μg, and hydromorphone 100 μg. If the anesthetic plan is altered (combined spinal-epidural, general anesthesia conversion, general anesthesia planned), indications and medication doses used will be noted for analysis.

Immediately following induction of anesthesia and prior to skin incision, infusion of study solution will be initiated.

Study solutions will consist of:

1. Control group: 100 mL 0.9% normal saline (NS).

2. Treatment group: 100 mL 0.9% NS containing 1g tranexamic acid (TA). Study solution will be infused via an infusion pump over 10 minutes. Blood loss will be measured by visual estimate and weight of surgical sponges. Noninvasive hemoglobin will be measured throughout the study. All routine care lab values will be noted. At minimum, one lab panel will be sent one hour after study solution initiation (hemoglobin, fibrinogen, platelet count, aPTT, PT, and TEG).

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking double blind (subject, caregiver, investigator, outcomes assessor)
Primary purpose prevention
(Placebo Comparator)
Patients at lower risk for postpartum hemorrhage during cesarean delivery, to receive standard of care NOT including tranexamic acid.
placebo; normal saline
0.9% Normal Saline
Patients at lower risk for postpartum hemorrhage during cesarean delivery, to receive standard of care AND tranexamic acid.
tranexamic acid
1 gram IV over 10 minutes

Primary Outcomes

Number of Subjects or Physicians Who Withdraw From Participation In the Study
time frame: from the time of patient consent through the end of data collection 6 weeks postpartum.
TEG values in Baseline, Control, and Treated Groups
time frame: one hour after initiation of study infusion
Intraoperative Blood Loss
time frame: during surgery in the operating room
Delayed Complications at the 6-Week Postpartum Visit With the Obstetrician.
time frame: 6 weeks postpartum

Eligibility Criteria

Female participants from 18 years up to 50 years old.

Inclusion Criteria: - American Society of Anesthesiologists (ASA) class I or II - aged 18-50 years - singleton vertex pregnancy - scheduled elective cesarean delivery (with or without prior labor) with a planned pfannensteil incision Exclusion Criteria: - allergy to tranexamic acid - history of inherited or acquired thrombophilia - history of deep vein thrombosis or pulmonary embolism, or use of anticoagulant medication. - preeclampsia, hemolysis, elevated liver enzymes, low platelet syndrome - seizure disorder

Additional Information

Official title The Influence of Prophylactic Tranexamic Acid on Thromboelastography During Cesarean Delivery: A Randomized, Double-Blind, Placebo-Controlled Trial
Trial information was received from ClinicalTrials.gov and was last updated in July 2016.
Information provided to ClinicalTrials.gov by Brigham and Women's Hospital.